Opioid Dependence Clinical Trial
— PRO-810Official title:
A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence
Verified date | June 2017 |
Source | Titan Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
Status | Terminated |
Enrollment | 9 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Voluntarily provide written informed consent prior to the conduct of any study related procedures - Male or female, 18-75 years of age - Meet the DSM-IV criteria for current opioid dependence - Females of childbearing potential and fertile males must use a reliable means of contraception Exclusion Criteria: - Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS) - Received treatment for opioid dependence (e.g., methadone, BPN) within the previous 90 days - Current diagnosis of chronic pain requiring opioids for treatment - Candidates for only short term opioid treatment or opioid detoxification therapy - Pregnant or lactating females - Previous hypersensitivity or allergy to BPN or EVA-containing substances or naloxone - Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) - Current history of coagulopathy, and/or anti-coagulant therapy (such as warfarin) - Meet the DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives) - Current use of benzodiazepines other than physician prescribed use - Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent - Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study - Participated in a clinical study within the previous 8 weeks - Previous participation in a Probuphine clinical trial - Presence of aspartate aminotransferase (AST) levels greater than or equal to 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels greater than or equal to 3 X upper limit of normal and/or total bilirubin greater than or equal to 1.5 X upper limit of normal and/or creatinine greater than or equal to 1.5 X upper limit of normal - Clinically significant low platelet count with current history of coagulopathy |
Country | Name | City | State |
---|---|---|---|
United States | Segal Institute For Clinical Research | Fort Lauderdale | Florida |
Lead Sponsor | Collaborator |
---|---|
Titan Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma BPN AUC(0-24)during 24 hours at steady state. | Day -1, Day -2 and Week 4 | ||
Secondary | Plasma BPN and NorBPN Cmax | week 4 | ||
Secondary | Time to maximum plasma BPN and NorBPN concentration (tmax) | Day -2, Day -1 and Day 1 | ||
Secondary | Plasma BPN and NorBPN AUC(0-24) during 24 hours at steady state | week 4 | ||
Secondary | Change in plasma BPN concentration | 24 weeks | ||
Secondary | Number of subjects with adverse events as a measure of safety and tolerability | Adverse events that occurred after the signing of informed consent until 14 days after study drug treatment has been discontinued, or AEs designated as possibly-related to study drug and Serious AEs until resolution or stabilization, were followed. | approx. 11 weeks (due to study termination) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03675386 -
Reducing Opioid Use for Chronic Pain Patients Following Surgery
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT02294253 -
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
|
Phase 2/Phase 3 | |
Completed |
NCT01592461 -
Starting Treatment With Agonist Replacement Therapies Follow-up Study
|
N/A | |
Completed |
NCT01741350 -
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
|
N/A | |
Terminated |
NCT04121546 -
Collaborative Care for Opioid Dependence And Pain Pilot Study
|
N/A | |
Withdrawn |
NCT03368794 -
Naloxone to TReatment Entry in the Emergency Setting
|
N/A | |
Completed |
NCT03447743 -
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
|
Early Phase 1 | |
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Recruiting |
NCT04189523 -
Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage
|
N/A | |
Completed |
NCT03305666 -
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
|
Phase 4 | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT01895270 -
Improving Buprenorphine Detoxification Outcomes With Isradipine
|
Phase 1/Phase 2 | |
Completed |
NCT01717963 -
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
|
Phase 3 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Completed |
NCT01425060 -
Improving Effective Contraceptive Use Among Opioid-maintained Women
|
Phase 1 | |
Completed |
NCT01188421 -
Medications Development for Drug Abuse Disorders
|
Phase 1/Phase 2 |